Press centre

Latest

12 Feb 2021

GARDP Welcomes Additional Funding from UK to Develop New Treatment for Gonorrhoea

The UK government has announced an additional £1.5 million of funding to develop a new treatment for gonorrhoea. This investment, on top of £3.5 million committed in 2019, will support GARDP in the development and availability of zoliflodacin, a novel antibiotic, which is currently being assessed as part of a global phase 3 trial for safety and effectiveness as a treatment for gonorrhoea.

27 Jan 2021

GARDP and Entasis Therapeutics Announce South Africa Site Activation in Global Phase 3 Study of Zoliflodacin as a New Gonorrhoea Treatment

20 Jan 2021

GARDP and BSAC Sign MOU to Collaborate on Antibiotic Resistance Education, Policy and Advocacy

17 Dec 2020

GARDP, Dr. Reddy’s and Aurigene Pharmaceutical Services Limited Sign MOU for Antibiotic Access Through Collaborative Model

30 Nov 2020

GARDP, FIND and WHO Agree to Explore Joint Initiatives That Could Help Combat Antimicrobial Resistance

18 Nov 2020

Early Lessons From the COVID-19 Can Help Tackle Silent Pandemic of Drug-Resistant Infections, Says New GARDP Report

4 Nov 2020

GARDP Appoints Hiroki Nakatani to Board and Hanan Balkhy as Board Observer

Media contacts

For media inquiries, please contact the GARDP Communications Department:

Phone: +41 22 555 19 90 | Email: communications@gardp.org

Cookie Policy

We use cookies to provide you a better experience and understand how our site is being used. To consent to the use of cookies, click ‘Accept’. Learn more about our cookie and privacy policy.